Total medical devices industry cross border deals worth $4.3bn were announced globally for November 2021, with the $2.49bn acquisition of Atos Medical being the sector’s biggest investment, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 40.9% over the previous month of $3.03bn and a drop of 37.2% when compared with the last 12-month average of $6.8bn.
In terms of number of cross border deals, the sector saw a rise of 3.77% with 55 deals in November 2021 when compared to the last 12-month average of 53 deals.
In value terms, Europe led the activity with cross border deals worth $2.67bn in November 2021.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDatamedical devices industry cross border deals in November 2021: Top deals
The top five cross border deals accounted for 81.3% of the overall value during November 2021.
The combined value of the top five cross border deals stood at $3.47bn, against the overall value of $4.3bn recorded for the month.
The top five medical devices industry cross border deals of November 2021 tracked by GlobalData were:
1) Coloplast $2.49bn acquisition deal with Atos Medical
2) The $475m acquisition of Ivantis by Alcon
3) Blue Bay capital,Boyu Capital Consultancy,Greater Bay Area Fund,Guoqi Investment,Jiangsu Jiequan ABC State-owned Enterprise Mixed Ownership Reform Fund,LYFE Capital,Mirae Asset Venture Investment,Morning One Investment,Octagon Capital Group,Orbimed Advisors,Sage Partners,Sanzheng Health Investment,Sequoia Capital China and Temasek Holdings (Private) $200m venture financing deal with Shenzhen Jingfeng Medical Technology
4) The $180m venture financing of Owkin by Sanofi
5) Atlas Venture,Casdin Capital,Cormorant Asset Management,Janus Henderson Investors,Newpath Management,Omega Fund Management,Sofinnova Partners,T Rowe Price Associates and Wellington ManagementLLP $125m venture financing deal with Chroma Medicine
